RS86

RRM1

RRM1, or Ribonucleotide Reductase M1, is a crucial enzyme subunit involved in the synthesis of deoxyribonucleotides from ribonucleotides, which are the building blocks of DNA. This process is essential for DNA replication and repair, making RRM1 a vital component in cellular proliferation and genomic stability.

Structure and Function

RRM1 is the large subunit of the ribonucleotide reductase (RNR) enzyme complex. It contains the catalytic site necessary for the reduction of ribonucleotides to deoxyribonucleotides. The enzyme operates by a radical-based mechanism, which involves the transfer of electrons to facilitate the reduction process.

RRM1 forms a heterodimer with the small subunit, RRM2 or RRM2B, depending on the cellular context and the phase of the cell cycle. The interaction between these subunits is critical for the enzyme's activity. RRM1 provides the binding sites for the ribonucleotide substrates and the allosteric effectors that regulate the enzyme's activity.

Regulation

The activity of RRM1 is tightly regulated at multiple levels:

• Transcriptional Regulation: The expression of RRM1 is controlled by cell cycle-dependent transcription factors. It is upregulated during the S phase of the cell cycle to meet the increased demand for deoxyribonucleotides during DNA replication.

• Allosteric Regulation: RRM1 activity is modulated by feedback inhibition through binding of deoxyribonucleoside triphosphates (dNTPs) to its allosteric sites. This ensures a balanced supply of dNTPs for DNA synthesis.

• Post-translational Modifications: Phosphorylation and other modifications can affect the stability and activity of RRM1.

Clinical Significance

RRM1 is a target for cancer therapy due to its role in DNA synthesis. Inhibitors of ribonucleotide reductase, such as hydroxyurea, are used to disrupt DNA replication in rapidly dividing cancer cells. Additionally, the expression level of RRM1 has been studied as a potential biomarker for the prognosis of certain cancers, including non-small cell lung cancer.

Research and Developments

Recent studies have focused on the development of novel inhibitors that specifically target RRM1, aiming to improve the efficacy and reduce the side effects of cancer treatments. Understanding the structural dynamics of RRM1 and its interaction with RRM2 is also a key area of research, providing insights into the design of more effective therapeutic agents.

Also see

• Ribonucleotide Reductase
• DNA Replication
• Cell Cycle
• Cancer Therapy
• Enzyme Regulation